Anke Biotech announced that AK2401 injection, a pabolizumab biosimilar drug independently developed by the company, recently obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and was approved to conduct clinical trials on solid tumors. This product is registered as a therapeutic biological product category 3.3: biosimilar.

Anke Biotech announced that AK2401 injection, a pabolizumab biosimilar drug independently developed by the company, recently obtained the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and was approved to conduct clinical trials on solid tumors. This product is registered as a therapeutic biological product category 3.3: biosimilar.